Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

28.61 -0.20 (-0.69%)
Official Closing Price Updated: 4:15 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
ALKERMES PLC (NASDAQ:ALKS) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:ALKS, an undervalued stock with good fundamentals.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
Why Alkermes Stock Is Sinking Today
The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors. 
Via The Motley Fool
Why NASDAQ:ALKS Is a Promising High-Growth Stock in the Midst of Consolidation.
ALKERMES PLC (NASDAQ:ALKS), a strong growth stock, setting up for a breakout. 
Via Chartmill
Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook
Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
Analysts say Alkermes' drug is clearly active. But investors have concerns. 
Via Investor's Business Daily
Alkermes Honors Women's Equality Day
Via ACCESSWIRE
Earnings Preview: Alkermes
Via Benzinga
Where Alkermes Stands With Analysts
Via Benzinga
Alkermes Earnings Perspective: Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Analyst Expectations for Alkermes's Future
Via Benzinga
The Latest Analyst Ratings for Alkermes
Via Benzinga
While growth is established for NASDAQ:ALKS, the stock's valuation remains reasonable.
Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS). 
Via Chartmill
NASDAQ:ALKS is showing good growth, while it is not too expensive.
Despite its growth, ALKERMES PLC (NASDAQ:ALKS) remains within the realm of affordability. 
Via Chartmill
Hovnanian Enterprises, LexinFintech Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones falling around 10 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega
Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56 
Via Benzinga
Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor
From Sarissa Capital Management LP
Via Business Wire
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
From Sarissa Capital Management LP
Via Business Wire
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
From Sarissa Capital Management LP
Via Business Wire
Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
From Sarissa Capital Management LP
Via Business Wire
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements
Via Benzinga
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.